Biography:

Dr. Feng Xu is Director of Department of Medical Technology and Pharmacy, Professor of Pharmacology, Fengxian Hospital, Southern Medical University, Shanghai. One of their renowned works are Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.